2bPrecise and PierianDx Collaborate to Deliver a Comprehensive Precision Medicine Solution

PITTSBURGH--(BUSINESS WIRE)-- 2bPrecise^®, LLC, an EHR-agnostic, cloud-based precision medicine platform, today announced it is collaborating with PierianDx, Inc., the leading clinical genomics knowledgebase company, to offer a comprehensive precision medicine solution that combines genomic and clinical data to help providers make precise decisions at the point of care.

“We believe the power of precision medicine can best be achieved by combining a patient’s clinical data with genomic results at the point of care,” said Assaf Halevy, founder and CEO of 2bPrecise. “To that end,” he adds, “the companies’ collaborative effort will not simply repurpose clinical and genomic data on the desktop, but also provide the only solution that integrates a patient’s next generation sequencing (NGS) lab results from commercial and internal labs with relevant and critical clinical information. It then facilitates interpretation and clinical action using a comprehensive knowledgebase comprised of scientific and evidence-based content, including previous patients’ outcomes.”

“Precision medicine has the potential to change the way care is delivered to patients today, but it also brings a new challenge for providers to make all of this data actionable,” said Halevy. “Our collaboration with PierianDx is being designed to help providers overcome this obstacle with a go-to resource to decipher genomic data in a patient-specific and efficient manner.”

Precision medicine should be applied to cancer patients of any stage now through holistic clinical, genomic, and knowledgebase integration, while supporting the most complex patients as part of a Molecular Tumor Board review. With this forward-looking collaboration, 2bPrecise, an Allscripts company, would bring evidence-based knowledge from PierianDx’s Clinical Genomics WorkSpace™ (CGW) platform, the industry’s leading integrated workspace for clinical genomic analytics, classification, interpretation and reporting, directly to the point of care.

“We anticipate that the synergies between our organizations will empower us to create a valuable solution offering that will enable a provider to utilize all of a patient’s clinical and genomic data to make treatment and clinical trial decisions,” said Michael Sanderson, CEO of PierianDx.

About PierianDx
At PierianDx we empower progressive health institutions and diagnostic laboratories to build world-class precision medicine programs. Our leading clinical genomics software and collaborative knowledgebase leverages the clinical expertise among our customers to solve the problem of translating complex genomic data into actionable insights for individual patients in any healthcare setting. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, our solutions deliver the most integrated and trusted approach across the clinical care spectrum. For more information, visit www.pieriandx.com.